General contact

Main switchboard

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST


Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999


Investor Relations

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Novartis announces first quarter results 2014
Commenting on the results, Joseph Jimenez, CEO of Novartis, said: “Novartis delivered a solid quarter, with all divisions contributing to growth. The milestones we achieved in the first quarter are a testament to our focus on science-based innovation.”
Featured news:
  • 03-Apr-2014 Novartis and partners unite in combatting neglected tropical diseases at event in Paris. Learn more »

  • 01-Apr-2014 Novartis is working with local partners to develop innovative approaches to improving human health in Africa. Learn more »

  • 25-Mar-2014 Novartis is investing in thermal energy storage to minimize fuel costs and reduce the carbon footprint of new buildings. Learn more »




Stock chart